The impact of a FLT3-internal tandem duplication (FLT3ITD) on prognosis of patients with acute myeloid leukemia (AML) is dependent on the ratio of mutated to wildtype allele. In 648 normal karyotype (NK) AML patients we found a significant independent effect of the quantitative FLT3ITD mRNA level -measured as (FLT3ITD/wtFLT3) / (FLT3ITD/wtFLT3 + 1) -on outcome. Moreover, this effect was clearly seen in 329 patients with a mutated NPM1 gene (NPM1+), but not in 319 patients without a NPM1 mutation (wtNPM1). In a multivariate 
Introduction
The prognosis of NK-AML is influenced by the presence of gene mutations. NPM1 has been shown to be the most common single mutated gene in NK-AML occurring with a frequency of about 50%. Combinations of NPM1 mutations with FLT3ITD have been described in about 20% of patients with NK-AML 1, 2 . The positive prognostic impact of the NPM1+ on outcome is mainly evident in patients lacking a FLT3ITD. About 60% of patients carrying the NPM1+/FLT3-wildtype genotype survive more than 10 years 3, 4 . The NPM1+ NK-AML has been classified as an own entity of favorable prognosis in the revised WHO and ELN classifications 5, 6 . Since 2001 there have been reports that not only the presence of a FLT3ITD per se, but that the FLT3ITD/FLT3-wildtype (wtFLT3) ratio is essential for prognosis 7, 8 . The aim of our work was to assess the influence of the FTL3ITD mRNA level according to the mutation status of NPM1.
Patients and methods
Patients: Our analyses were based on patients with NK-AML treated within the AMLCG99 study 9 . Patients were randomly assigned for induction therapy with either TAD (thioguanine, conventional-dose AraC, daunorubicin) followed by HAM (high-dose AraC, mitoxantrone) or two courses of HAM. As consolidation therapy in first complete remission (CR), allogeneic transplantation from an unrelated donor was recommended for high risk patients <60 years whereas all other patients received treatment with TAD and maintenance therapy 9 .
Endpoints: Overall survival (OS) was calculated from randomization to death from
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Molecular Analyses: Mutation analyses of NPM1, FLT3ITD, FLT3TKD, MLL-PTD and
CEBPA were performed according to standard protocols previously described [10] [11] [12] . FLT3
mRNA RT-PCR and PCR were performed according to standard protocols 13 . Labelled PCR products were electrophoresed on ABI 3100 according to protocol (Applied Biosystems). The data were collected and analyzed with Genescan and Genotyper software (Applied Biosystems). The ratio of FLT3ITD mRNA to wtFLT3 mRNA was calculated as previously published 8, 14 . The amount of FLT3ITD mRNA in relation to the entire FLT3 transcript signal was defined as: quantitative "FLT3ITD mRNA level" = (FLT3ITD/wtFLT3) / (FLT3ITD/wtFLT3 + 1). 
Results and Discussion
Analyses were performed in 648 of 802 patients treated within the AMLCG99 trial (supplementary Figure 1) . 119/648 patients received allogeneic transplantation in first CR.
Median follow-up for OS was 62. 
Impact of FLT3ITD mutation level on OS and definition of thresholds
Univariate Cox regression showed a significant impact of the FLT3ITD mRNA level Figure 1A ). FLT3ITD mRNA level may not impact on survival in patients with wtNPM1, although this conclusion is limited by the low statistical power due to the relatively small number of patients with a high FLT3ITD mRNA level (n=9; 1%).
In the multivariate Cox regression model with all 648 patients, the independent prognostic impact of the quantitative FLT3ITD mRNA level on outcome was detectable in NPM1+ patients (p<0.001), but not in wtNPM1 ( Table 1) . This was true for both age subgroups (</≥ 60 years, data not shown). In multiple regression in NPM1+ patients, the FLT3ITD low-level group had an adjusted hazard ratio of 1.5 (95% CI 0.96-2.3) for OS (p=0.078), and the 
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Tables:
The independent prognostic impact of the FLT3ITD mutation level on overall survival (OS) and relapse free survival (RFS) was evaluated using multivariate Cox regression models. The FLT3ITD mutation level was introduced as a continuous parameter into the model. Due to the known interaction between NPM1 and FLT3ITD an interaction term NPM1*FLT3ITD mutation level was included in the model. Besides the FLT3ITD mutation level, mutations of the molecular markers NPM1 (NPM1+), CEBPA (moCEBPA=monoallelic CEBPA mutation; biCEBPA=biallelic CEBPA mutation), FLT3TKD, MLL-PTD, and the clinical parameters age, sex, ECOG performance status, AML de novo, white blood count (WBC), platelet count, hemoglobin level, lactase dehydrogenase (LDH) and amount of bone marrow blasts were introduced into the model. The multivariate prognostic factors were identified using a logistic regression model with a significance level of 5%.
HR=Hazard. CI= confidence interval, CL=confidence limit, P =p value; n=number. 
